Published in Obesity and Diabetes Week, December 6th, 2004
"The ability to slow or prevent kidney failure in patients with IgA nephropathy has the potential to improve patient quality of life as well as to reduce a portion of the billions of dollars spent annually on dialysis and renal transplantation," stated Timothy M. Shannon, MD, executive vice president research and development and chief medical officer at CuraGen. "We are excited to be...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week